FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/48QLLoMvUk https://t.co/mf4IBVLZD9
Links:
FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleuk…
https://bit.ly/48IMSaa
Oct-10-2023
